Trium Capital’s Achilles Therapeutics ACHL Stock Holding History

Trium Capital’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$91K	Buy	61,506 +30,753	+100%	+$45.5K	0.06%	42
2026 Q1	$45.5K	Buy	+30,753	New	+$45.5K	0.03%	43

Other funds holding ACHL

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Trium Capital's ACHL Position: Q2 2026 in Review

Trium Capital increased its Achilles Therapeutics (ACHL) stake by 100% in Q2 2026, buying an estimated $45.5K and bringing the position to 61,506 shares worth $91K. The position accounts for 0.06% of the portfolio, ranked #42.

Trium Capital first reported a position in ACHL in Q1 2026 and has held it in 2 quarters since. 2 funds tracked by Wall St. Rank hold ACHL as of Q2 2026.

Trium Capital held 61,506 shares of Achilles Therapeutics worth $91K as of Q2 2026.
Trium Capital bought 30,753 Achilles Therapeutics shares in Q2 2026, an estimated $45.5K.
Achilles Therapeutics made up 0.06% of Trium Capital's portfolio in Q2 2026, its #42 holding.
Trium Capital first reported a position in Achilles Therapeutics in Q1 2026 and has held it in 2 quarters since.
2 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2026.

Based on Trium Capital's 13F filing for Q2 2026, filed 16 Jul 2026.